Allosteric Regulation

Allosteric Regulation Basics - Switch On, Switch Off

• Allosteric Enzyme: An enzyme with an allosteric site, distinct from its active site, allowing activity modulation.
• Allosteric Site: 📌 'Allo' = 'other'. Specific regulatory site on the enzyme, separate from active site, where effectors bind.
• Allosteric Effectors (Modulators): Small molecules binding to allosteric sites, altering enzyme activity (↑ positive, ↓ negative).
  • Positive Effectors (Activators): ↑ enzyme activity.
  • Negative Effectors (Inhibitors): ↓ enzyme activity.
• Key Characteristics:
  • Reversible, non-covalent effector binding.
  • Induces conformational change, transmitted to active site, altering substrate affinity/catalytic rate.

⭐ Allosteric enzymes are often oligomeric (multisubunit) proteins, enabling cooperativity.

Allosteric Mechanisms & Models - Shape Shifters at Work

Allosteric enzymes: effectors bind to allosteric sites (not active site), inducing conformational changes altering activity.

• Conformational States:
  • T (Tense) state: ↓ affinity, favored by inhibitors.
  • R (Relaxed) state: ↑ affinity, favored by activators.
• Cooperativity: Ligand binding affects further binding.
  • Homotropic: Substrate as effector (e.g., O₂ for Hb).
  • Heterotropic: Different effector (e.g., ATP/CTP for ATCase).

• Models of Allostery:

  Feature	MWC (Concerted)	KNF (Sequential)
  Transition	All subunits change simultaneously	Sequential change, induced fit
  Pre-existing Eqm.	Yes ($T \rightleftharpoons R$ equilibrium)	Ligand induces fit; sequential change
  Symmetry	Preserved (all-T or all-R)	Intermediates (mixed T/R) possible
  Negative Coop.	Not easily explained	Can explain

⭐ The MWC model assumes all subunits change conformation simultaneously, while the KNF model allows for sequential changes.

Allosteric Enzyme Kinetics - Curve Ball Kinetics

• Curve: Sigmoidal (S-shaped) v vs. [S] plot, distinct from Michaelis-Menten's hyperbolic curve. Indicates cooperativity.
• K0.5: [S] for 1/2 $V_{max}$; reflects enzyme affinity in allosteric enzymes.
• Allosteric Activators:
  • Shift curve left (↓K0.5, ↑affinity).
  • Favor R (relaxed, high-affinity) state.
  • Types: K-type (↓K0.5), V-type (↑$V_{max}$).
• Allosteric Inhibitors:
  • Shift curve right (↑K0.5, ↓affinity).
  • Favor T (taut, low-affinity) state.
  • Types: K-type (↑K0.5), V-type (↓$V_{max}$).
• Hill Equation: Describes cooperativity: $v = V_{max} [S]^{n_H} / (K_{0.5}^{n_H} + [S]^{n_H})$.
• Hill Coefficient ($n_H$): Measures degree of cooperativity.
  • $n_H > \textbf{1}$: Positive cooperativity.
  • $n_H < \textbf{1}$: Negative cooperativity.
  • $n_H = \textbf{1}$: No cooperativity (Michaelis-Menten like).

⭐ Positive cooperativity: one substrate binding increases the enzyme's affinity for subsequent substrate molecules.

Key Examples & Clinical Impact - Allostery in Action

Key allosteric molecules:

• Phosphofructokinase-1 (PFK-1): Pivotal enzyme in glycolysis.

  • Activators: AMP, Fructose-2,6-bisphosphate (signal low energy).
  • Inhibitors: ATP, Citrate (signal high energy).
  • 📌 PFK-1: 'ATP inhibits, AMP activates Progress of glycolysis'.

  ⭐ High ATP levels allosterically inhibit PFK-1, signaling that the cell has sufficient energy.

• Aspartate Transcarbamoylase (ATCase): Early step in pyrimidine biosynthesis.

  • Activator: ATP.
  • Inhibitor: CTP (end-product feedback inhibition).

• Hemoglobin (Hb): Classic allosteric protein (not an enzyme), crucial for $O_2$ transport.

  • Homotropic positive effector: $O_2$.
  • Heterotropic negative effectors: $H^+$, $CO_2$, 2,3-Bisphosphoglycerate (2,3-BPG).

• Clinical Relevance: Allosteric drugs act as precise modulators.
  • Examples: Cinacalcet (CaSR in parathyroid disorders), Maraviroc (CCR5 in HIV).

High‑Yield Points - ⚡ Biggest Takeaways

• Allosteric enzymes possess regulatory sites distinct from their active sites.
• Binding of allosteric modulators (activators or inhibitors) causes conformational changes.
• They typically display sigmoidal kinetics (cooperativity), not Michaelis-Menten.
• Homotropic effectors are substrates; heterotropic effectors are non-substrate molecules.
• PFK-1 (glycolysis) is a classic example, regulated by ATP (inhibitor) and AMP (activator).
• This regulation provides fine-tuned control over metabolic pathways.
• K-type modulators alter Km (substrate affinity); V-type modulators alter Vmax (maximal velocity).